Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 5Thoracic 4Lymphoid 4Gynecologic 3Gastrointestinal 3Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Dermatologic 2CNS 2

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

duvelisib 2obinutuzumab 1chiauranib 1Panobinostat 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × Lymphoid × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

National Cancer Centre, Singapore

Phase 1 Unknown
49 enrolled
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

NCT02598570 2017-02-06

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

AbbVie

Phase 1 Completed
7 enrolled
Lymphoid

Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡